The development of anthracycline analogs (review).
The anthracycline class of antitumour agents have the widest spectrum of activity of all drugs used to treat malignant disease. Consequently they are ubiquitous in their use worldwide, but are not without problems. The abrogation of cardiac toxicity and the development of drug resistance has been attempted by modifying the molecule chemically, producing over 1000 structural analogues since the discovery of Daunorubicin in the late 1950's. This review charts this developmental process and points to the possible future of this important class of drugs.